ONC (BeiGene Oncology) צמיחת רווח למניה בשנה הנוכחית

Reviewing the annual earnings per share history for BeiGene Ltd (ONC) on GURU.Markets, it is evident that the metric remains at 235.40. BeiGene Ltd (ONC) dominates the development of targeted therapies through its global network of clinical trials. High R&D expenditures are offset by the scalability of its molecules, while stable demand for Brukinsa ensures a powerful cash flow.

The global expansion of innovative oncology drugs from BeiGene Ltd (ONC) converts directly into growth in net income available to shareholders. This metric measures the percentage deviation of current earnings per share from the same period last year, allowing investors to assess the business scaling pace and the issuer's fundamental stability through year-over-year EPS dynamics.